Focus: Keros Therapeutics is a public biotech focused on rare muscle disorders and rare diseases, headquartered in Lexington, MA with a lean operational footprint and early-stage pipeline.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Cooling — net -10 jobs in 30d
2 added, 12 removed. Slower than typical.
Best suited for early-career scientists seeking deep research immersion in rare disease biology with runway to see Phase 3 readouts in 2-3 years.
Help build intelligence for Keros Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Keros Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms Stock Titan
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March MarketBeat
Is Keros Therapeutics (KROS) Stock heavily shorted | Price at $12.50, Up 2.12% - Viral Momentum Stocks - Xã Thanh Hà
Is Keros Therapeutics (KROS) Stock heavily shorted | Price at $12.50, Up 2.12% - Viral Momentum Stocks Xã Thanh Hà
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts MarketBeat
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo